

In the claims:

Following is a complete listing of the claims pending in the application, as amended:

1. (Currently amended) A topical delivery system, comprising:
a gemini surfactant in admixture with a biologically active agent, wherein the delivery system, when in contact with skin or a mucosal membrane, provides a ~~localized or systemic~~ therapeutic effect.
2. (Currently amended) The delivery system according to claim 1, wherein the gemini surfactant is selected from the group consisting of an anionic gemini surfactant, a gemini cationic surfactant, a neutral gemini surfactant, an amphoteric gemini surfactant, and/or mixtures thereof.
3. (Currently amended) The delivery system according to claim 1-~~or claim 2~~, wherein the gemini cationic surfactant has a hydrophobic tail comprising a C₃-C₃₀ alkyl group.
4. (Currently amended) The delivery system according to ~~any one of claims 1-3~~claim 1, wherein the biologically active agent is a plasmid DNA.
5. (Previously presented) The delivery system according to claim 4, wherein the plasmid DNA comprises a gene encoding for interferon- γ .
6. (Currently amended) The delivery system according to ~~any one of claims 1-5~~claim 1, wherein the delivery system includesfurther comprises one or more pharmaceutically-acceptable vehicles.
7. (Currently amended) The delivery system according to ~~any one of claims 1-5~~claim 1, wherein the delivery system includesfurther comprises one or more supplements suitable for application for skin or mucosa.

8. (Currently amended) The delivery system according to claim 6-~~or~~⁷, wherein the delivery system is formulated to have a form selected from the group consisting in the form of a cream, a lotion, a paste, an ointment, a foam, a gel, a lipid formulation, an emulsion, a solution, or~~and~~ a suspension.

9. (Currently amended) The delivery system according to claim 8, further comprising one or more supplements selected from a neutral carrier ~~or~~and a permeation enhancer.

10. (Previously presented) The delivery system according to claim 9, wherein the neutral carrier is selected from 1,2-dioleyl-sn-glycero-phosphatidylethanolamine (DOPE) or cholesterol.

11. (Previously presented) The delivery system according to claim 8, further comprising a compound selected from diethylene glycol monoethyl ether, polyglyceryl 3-diisostearate, PEG-8 caprylic and capric glycerides, and octyldodecyl myristate.

12.-19. (Cancelled)

20. (New) A method for treatment of a skin disorder, comprising topically delivering a delivery system according to claim 1.

21. (New) The method according to claim 20, wherein said delivering comprises delivering to a subject having a skin disorder selected from the group consisting of scleroderma, atopic dermatitis, and psoriasis.

22. (New) The method according to claim 20, wherein said delivering comprises delivering to a subject having a skin disorder of genetic origin.

23. (New) A method for treatment of a metabolic disease, comprising topically delivering a delivery system according to claim 1, wherein said metabolic disease is selected from the group consisting of gyrate atrophy, maternal hyperphenylalaninemia, familial hypercholesterolemia, and phenylketonuria.